Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 287

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Open access
Pal, Sumanta K, Tangen, Catherine, Thompson, Ian M, Balzer-Haas, Naomi, George, Daniel J, Heng, Daniel Y C, Shuch, Brian, Stein, Mark, Tretiakova, Maria, Humphrey, Peter, Adeniran, Adebowale, Narayan, Vivek, Bjarnason, Georg A, Vaishampayan, Ulka, Alva, Ajjai, Zhang, Tian, Cole, Scott, Plets, Melissa, Wright, John, Lara, Primo N·2021·The Lancet

Abstract

SUMMARY Background: MET signaling is a key driver of papillary renal cell carcinoma (PRCC). Given that there is no optimal therapy for metastatic PRCC, we sought to compare an existing standard (sunitinib) to MET kinase inhibitors. Methods: We conducted a randomized, open-label, phase II trial involving patients with metastatic PRCC who had received up to one prior therapy (excluding vascular endothelial growth factor-directed agents). Patients were assigned to receive sunitinib, cabozantinib, crizotinib or savolitinib, with stratification by receipt of prior therapy and PRCC subtype. Progression-free survival (PFS) was the primary endpoint. With 41 eligible patients per arm, there was 85% power to detect a 75% improvement in median PFS in each experimental arm compared to sunitinib, employing a one-sided alpha of 0.10 for each test. Findings: Overall, 152 patients were enrolled. Enrollment to savolitinib (N=29) and crizotinib (N=28) arms was halted after a pre-specified futility analysis; planned accrual was completed for both sunitinib (N=46) and cabozantinib (n=44) arms. PFS was longer with cabozantinib versus sunitinib (9.0 months vs. 5.6 months; hazard ratio for progression or death, 0.60; 95% CI 0.37–0.97, P=0.019 [1-sided]). Response rate for cabozantinib was 23% versus 4% for sunitinib (2-sided P=0.010). Savolitinib and crizotinib did not improve PFS relative to sunitinib. Grade 3 or 4 adverse events occurred in 69%, 74%, 37% and 39% of patients receiving sunitinib, cabozantinib, crizotinib and savolitinib, respectively; one grade 5 thromboembolic event was seen with cabozantinib. Interpretation: Cabozantinib resulted in significantly longer PFS when compared to sunitinib in patients with metastatic PRCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)00152-5

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 287

Metadata

Authors
Pal, S. K., Tangen, C., Thompson, I. M., Balzer-Haas, N., George, D. J., Heng, D. Y. C., Shuch, B., Stein, M., Tretiakova, M., Humphrey, P., Adeniran, A., Narayan, V., Bjarnason, G. A., Vaishampayan, U., Alva, A., Zhang, T., Cole, S., Plets, M., Wright, J., & Lara, P. N.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-02
Volume
397
Issue
10275
Pages
695-703
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3129780093
Cited by
287
References
24
FWCI
28.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00152-5
The paper
Pal, S. K., Tangen, C., Thompson, I. M., Balzer-Haas, N., George, D. J., Heng, D. Y. C., Shuch, B., Stein, M., Tretiakova, M., Humphrey, P., Adeniran, A., Narayan, V., Bjarnason, G. A., Vaishampayan, U., Alva, A., Zhang, T., Cole, S., Plets, M., Wright, J., & Lara, P. N. (2021). A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)00152-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.